Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 CTXR | Healthcare | $0.54 | 173.13K | $13.19M | -0.25 | ― | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CTXR | Citius Pharmaceuticals | 0.54 | -0.48 | -47.33% |
| Name | Price | % Change | |
|---|---|---|---|
| CTXR | $0.54 | -47.33% |
Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On November 4, 2026, Citius Oncology, Citius Pharmaceuticals’ majority-owned subsidiary, announced health-related quality-of-life results from pivotal Study 302 of LYMPHIR in
Citius Oncology (CTOR)announced preliminary, unaudited LYMPHIR unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026. Preliminary Fiscal Fourth Quarter 2026 Highlights:
An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On August 17, 2026, Citius Pharmaceuticals disclosed that Nasdaq granted the company an extension until February 8, 2027, to
Citius Pharma (CTXR) is scheduled to report 3rd quarter earnings on 08/17/2026. Regarding Q3 estimates, Wall Street analysts expect Citius Pharma to post earnings of -$0.36 per share. Revenue expectations
Citius Pharmaceuticals ( ($CTXR) ) has issued an update. On August 5, 2026, Citius Oncology reported strong commercial momentum for LYMPHIR’s U.S. launch, highlighting rapid uptake among treatment centers and
Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), provided an update on the expanding base of institutions ordering LYMPHIR, or denileukin diftitox-cxdl through wholesalers, continued formulary progress at
Citius Oncology (CTOR), majority-owned subsidiary of Citius Pharmaceuticals (CTXR), provided an update on the commercial launch of Lymphir – denileukin diftitox-cxdl -. Citius Oncology has expanded its commercial organization to
Citius Pharmaceuticals ( ($CTXR) ) has shared an announcement. On June 1, 2026, Citius Oncology reported Phase 1 data from an investigator-initiated study of LYMPHIR (denileukin diftitox-cxdl) in combination with
Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), highlighted Phase 1 clinical data presented May 30 at the American Society of Clinical Oncology Annual Meeting evaluating Lymphir in
Analysts are intrested in these 5 stocks: ( ($CTXR) ), ( ($AMT) ), ( ($JAZZ) ), ( ($CTMX) ) and ( ($FATE) ). Here is a breakdown of their recent
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| CTXR | buy | Reiterated | Aug 20, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| CTXR | Dec 17, 2026TBA | $13.19M | $-0.41 | $2.94M | 0.01 | -0.25 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
